These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 10764968

  • 1. Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America).
    Biedenbach DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2000 Apr; 36(4):255-9. PubMed ID: 10764968
    [Abstract] [Full Text] [Related]

  • 2. Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program.
    Johnson DM, Sader HS, Fritsche TR, Biedenbach DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2003 Sep; 47(1):373-6. PubMed ID: 12967753
    [Abstract] [Full Text] [Related]

  • 3. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
    Biedenbach DJ, Jones RN, Pfaller MA, Sentry Participants Group (Americas and Europe).
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):245-50. PubMed ID: 11404068
    [Abstract] [Full Text] [Related]

  • 4. Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999).
    Gales A, Sader H, Jones RN, SENTRY Participants Group (Latin America).
    Antimicrob Agents Chemother; 2001 May; 45(5):1463-6. PubMed ID: 11302811
    [Abstract] [Full Text] [Related]

  • 5. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).
    Jones RN, Biedenbach DJ.
    Diagn Microbiol Infect Dis; 2003 Apr; 45(4):273-8. PubMed ID: 12729999
    [Abstract] [Full Text] [Related]

  • 6. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
    Sader HS, Gales AC, Granacher TD, Pfaller MA, Jones RN, SENTRY Study Group (Latin America).
    Braz J Infect Dis; 2000 Oct; 4(5):245-54. PubMed ID: 11063556
    [Abstract] [Full Text] [Related]

  • 7. Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study.
    Jones ME, Staples AM, Critchley I, Thornsberry C, Heinze P, Engler HD, Sahm DF.
    Diagn Microbiol Infect Dis; 2000 Jul; 37(3):203-11. PubMed ID: 10904194
    [Abstract] [Full Text] [Related]

  • 8. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN, Fritsche TR, Sader HS, Stilwell MG.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [Abstract] [Full Text] [Related]

  • 9. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
    Bogdanovich T, Clark C, Ednie L, Lin G, Smith K, Shapiro S, Appelbaum PC.
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2050-7. PubMed ID: 16723565
    [Abstract] [Full Text] [Related]

  • 10. In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999).
    Bell JM, Turnidge JD, Pfaller MA, Jones RN.
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):315-8. PubMed ID: 12151193
    [Abstract] [Full Text] [Related]

  • 11. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections.
    Hoban D, Felmingham D.
    J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():49-59. PubMed ID: 12239228
    [Abstract] [Full Text] [Related]

  • 12. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003).
    Johnson DM, Stilwell MG, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):69-74. PubMed ID: 16546341
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
    Morrissey I, Robbins M, Viljoen L, Brown DF.
    J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
    [Abstract] [Full Text] [Related]

  • 14. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.
    Davies TA, Kelly LM, Hoellman DB, Ednie LM, Clark CL, Bajaksouzian S, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2000 Mar; 44(3):633-9. PubMed ID: 10681330
    [Abstract] [Full Text] [Related]

  • 15. Molecular characterization of fluoroquinolones, macrolides, and imipenem resistance in Haemophilus influenzae: analysis of the mutations in QRDRs and assessment of the extent of the AcrAB-TolC-mediated resistance.
    Cherkaoui A, Gaïa N, Baud D, Leo S, Fischer A, Ruppe E, François P, Schrenzel J.
    Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2201-2210. PubMed ID: 30145620
    [Abstract] [Full Text] [Related]

  • 16. Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.
    Jones RN, Biedenbach DJ, Erwin ME, Beach ML, Pfaller MA.
    J Clin Microbiol; 1999 Jun; 37(6):1999-2002. PubMed ID: 10325362
    [Abstract] [Full Text] [Related]

  • 17. Molecular characterization of fluoroquinolone resistance in nontypeable Haemophilus influenzae clinical isolates.
    Puig C, Tirado-Vélez JM, Calatayud L, Tubau F, Garmendia J, Ardanuy C, Marti S, de la Campa AG, Liñares J.
    Antimicrob Agents Chemother; 2015 Jan; 59(1):461-6. PubMed ID: 25385097
    [Abstract] [Full Text] [Related]

  • 18. Fluoroquinolone resistance in Haemophilus influenzae from nursing home residents in Taiwan: correlation of MICs and mutations in QRDRs.
    Chang CM, Shih HI, Wu CJ, Lauderdale TL, Lee NY, Lee CC, Chen YC, Huang CC, Ko WC.
    J Appl Microbiol; 2020 Jun; 128(6):1624-1633. PubMed ID: 31951091
    [Abstract] [Full Text] [Related]

  • 19. [Serotype distribution and drug resistance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated from nasopharynx of Uygur children].
    Tian HL, Shi W, Zhou HF, Yuan L, Yao KH, Rexiati D, Xu AM.
    Zhonghua Er Ke Za Zhi; 2018 Apr 02; 56(4):279-283. PubMed ID: 29614568
    [Abstract] [Full Text] [Related]

  • 20. Mutant selection window of four quinolone antibiotics against clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
    Nakai H, Sato T, Uno T, Furukawa E, Kawamura M, Takahashi H, Watanabe A, Fujimura S.
    J Infect Chemother; 2018 Feb 02; 24(2):83-87. PubMed ID: 29290527
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.